P1068: RISK-ADJUSTED SAFETY ANALYSIS OF PACRITINIB IN PATIENTS WITH MYELOFIBROSIS by A. Vannucchi, N. Pemmaraju, B. Scott, M. Savona, S. Oh, F. Palandri, H. K. Al-Ali, M. Sobas, M. F. McMullin, V. Gupta, A. Yacoub, R. Mesa, S. Buckley, K. Roman-Torres, S. Verstovsek, C. Harrison

Get full text

P1050: THROMBOCYTOPENIC MYELOFIBROSIS (MF) PATIENTS PREVIOUSLY TREATED WITH A JAK INHIBITOR IN A PHASE 3 RANDOMIZED STUDY OF MOMELOTINIB (MMB) VERSUS DANAZOL (DAN) [MOMENTUM] by A. Vannucchi, R. Mesa, A. Gerds, H. K. Al-Ali, D. Lavie, A. Kuykendall, S. Grosicki, A. Iurlo, Y. T. Goh, M. Lazaroiu, M. Egyed, M. L. Fox, D. McLornan, A. Perkins, S.-S. Yoon, V. Gupta, J.-J. Kiladjian, R. Donahue, J. Kawashima, S. Verstovsek

Get full text

S195: MOMENTUM: PHASE 3 RANDOMIZED STUDY OF MOMELOTINIB (MMB) VERSUS DANAZOL (DAN) IN SYMPTOMATIC AND ANEMIC MYELOFIBROSIS (MF) PATIENTS PREVIOUSLY TREATED WITH A JAK INHIBITOR by S. Verstovsek, A. Vannucchi, A. Gerds, H. K. Al-Ali, D. Lavie, A. Kuykendall, S. Grosicki, A. Iurlo, Y. T. Goh, M. Lazaroiu, M. Egyed, M. L. Fox, D. McLornan, A. Perkins, S.-S. Yoon, V. Gupta, J.-J. Kiladjian, R. Donahue, J. Kawashima, R. Mesa

Get full text

P1030: MANIFEST-2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL STUDY OF PELABRESIB (CPI-0610) AND RUXOLITINIB VS PLACEBO AND RUXOLITINIB IN JAK INHIBITOR-NAÏVE MYEL... by C. Harrison, R. K. Rampal, V. Gupta, S. Verstovsek, M. Talpaz, J.-J. Kiladjian, R. Mesa, A. Kuykendall, A. Vannucchi, F. Palandri, S. Grosicki, T. Devos, E. Jourdan, M. J. Wondergem, H. K. Al-Ali, V. Buxhofer-Ausch, A. Alvarez-Larrán, S. Akhani, R. Muñoz-Carerras, Y. Sheykin, G. Colak, M. Harris, J. Mascarenhas

Get full text